Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion

Neurochemistry International

Volumn 51, Issue 6-7, 2007, Pages 412-423

  Helkamaa, Teemu ^a   Reenilä, Ilkka ^a   Tuominen, Raimo K ^b   Soinila, Seppo ^a,c   Väänänen, Antti ^a   Tilgmann, Carola ^d   Rauhala, Pekka ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d ORION CORPORATION   (Finland)

Author keywords

Catechol O methyltransferase; Dopamine; l Dopa; Lipopolysaccharide; Microglia; OX 42; Parkinson's disease; Substantia nigra

Indexed keywords

CATECHOL METHYLTRANSFERASE; ENTACAPONE; LEVODOPA; LIPOPOLYSACCHARIDE; TOLCAPONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CELL ACTIVATION; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; ENZYME INHIBITION; GLIA CELL; IMMUNOREACTIVITY; INFLAMMATION; MACROPHAGE; MALE; MICROGLIA; NERVE CELL LESION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SUBSTANTIA NIGRA; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD11B; BIOLOGICAL MARKERS; CATECHOL O-METHYLTRANSFERASE; DOPAMINE; ENCEPHALITIS; ENZYME ACTIVATION; GLIOSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; LEVODOPA; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; PARKINSON DISEASE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; UP-REGULATION;

RATTUS;

EID: 34848926047     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.04.020     Document Type: Article

References (74)

1. Akiyama H., and McGeer P.L. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res. 489 2 (1989) 247-253
2. Arai H., Furuya T., Yasuda T., Miura M., Mizuno Y., and Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin 1β, and expression of caspase-11 in mice. J. Biol. Chem. 279 49 (2004) 51647-51653
3. Asanuma M., Miyazaki I., Diaz-Corrales F.J., and Ogawa N. Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med. Okayama 58 5 (2004) 221-233
4. Bollen M., Gijsbers R., Ceulemans H., Stalmans W., and Stefan C. Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit. Rev. Biochem. Mol. 35 6 (2000) 393-432
5. Bradbury M.W.B. The blood-brain barrier: transport across the cerebral endothelium. Circ. Res. 57 (1985) 213-222
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
7. Burrel R. Immunomodulation by bacterial endotoxin. Crit. Rev. Microbiol. 17 (1990) 188-208
8. Castano A., Herrera A.J., Cano J., and Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 70 (1998) 1584-1592
9. Castano A., Herrera A.J., Cano J., and Machado A. The degenerative effect of a single intranigral injection of LPS is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and INF-gamma. J. Neurochem. 81 1 (2002) 150-157
10. Cheng L., Allore R.J., and Richardson P.M. Entry of monocytes into the brain after injection of Corynebacterium parvum. Exp. Neurol. 149 (1998) 322-328
11. Davis E.J., Foster T.D., and Thomas W.E. Cellular forms and functions of brain microglia. Brain Res. Bull. 34 (1994) 73-78
12. de Boer A.G., and Gaillard P.J. Blood-brain-barrier dysfunction and recovery. J. Neural Transm. 113 4 (2006) 455-462
13. De Pablos R.M., Herrera A.J., Villaran R.F., Cano J., and Machado A. Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB J. 19 3 (2005) 407-409
14. De Vries H.E., Kuiper J., de Boer A.G., van Berkel T.J., and Breimer D.D. The blood-brain barrier in neuroinflammatory diseases. Pharmacol. Rev. 49 (1997) 143-155
15. Edelson P.J., and Erbs C. Plasma membrane localization and metabolism of alkaline phosphodiesterase I in mouse peritoneal macrophages. J. Exp. Med. 147 (1978) 77-86
16. Floyd R.A. Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic. Biol. Med. 26 (1999) 1346-1355
17. Ford A.L., Goodsall A.L., Hickey W.C., and Sedgwick J.D. Normal adult microglia separated from other central nervous system macrophages by flow cytometric sorting. J. Immunol. 154 (1995) 4309-4321
18. Forsberg M.M., Lehtonen M., Heikkinen M., Savolainen J., Järvinen T., and Männistö P.T. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in rat. J. Pharmacol. Exp. Ther. 304 (2003) 498-506
19. Forsberg M.M., Juvonen R.O., Helisalmi P., Leppänen J., Gogos J.A., Karayiorgou M., and Männistö P.T. Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 370 4 (2004) 279-289
20. Gehrmann J., Matsumoto Y., and Kreutzberg G.W. Microglia: intrinsic immuneffector cell of the brain. Brain Res. Rev. 20 (1995) 269-287
21. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21 (2006) 404-412
22. Gordin A., Kaakkola S., and Teräväinen H. Position of COMT inhibition in the treatment of Parkinson's disease. Adv. Neurol. 91 (2003) 237-250
23. Guldberg H.C., and Marsden C.A. Catechol-O-methyltransferase: Pharmacological aspects and physiological role. Pharmacol. Rev. 27 (1975) 135-206
24. Haramaki N., Stewart D.B., Aggarwal S., Kawabata T., and Packer L. Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury. Biochem. Pharmacol. 50 (1995) 839-843
25. Helkamaa T., Finckenberg P., Louhelainen M., Merasto S., Rauhala P., Lapatto R., Cheng Z.J., Reenilä I., Männistö P., Muller D.N., Luft F.C., and Mervaala E.M. Entacapone protects from angiotensin II-induced inflammation and renal injury. J. Hypertens. 21 (2003) 2353-2363
26. Herrera A.J., Castano A., Venero J.L., Cano J., and Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 7 (2000) 429-447
27. Herrera A.J., Tomas-Camardiel M., Venero J.L., Cano J., and Machado A. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J. Neural Transm. 112 1 (2005) 111-119
28. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., and Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 106 (2003) 518-526
29. Iravani M., Leung C., Sadeghian M., Haddon C., Rose S., and Jenner P. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur. J. Neurosci. 22 (2005) 317-330
30. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59 (2000) 1233-1250
31. Kaakkola S., Männistö P.T., and Nissinen E. Striatal membrane-bound and soluble catechol-O-methyltransferase after selective neural lesions in the rat. J. Neural Transm. 69 (1987) 221-228
32. Karhunen T., Tilgmann C., Ulmanen I., Julkunen I., and Panula P. Distribution of catechol-O-methyltransferase enzyme in rat tissues. J. Histochem. Cytochem. 42 (1994) 1079-1090
33. Karhunen T., Tilgmann C., Ulmanen I., and Panula P. Catechol-O-methyltransferase (COMT) in rat brain: immunoelectron microsopic study with an antiserum against rat recombinant COMT protein. Neurosci. Lett. 187 (1995) 57-60
34. Kato H., Takahashi A., and Itoyama Y. Cell cycle protein expression in proliferating microglia and astrocytes following transient global cerebral ischemia in the rat. Brain Res. Bull. 60 3 (2003) 215-221
35. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., and Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20 16 (2000) 6309-6316
36. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19 8 (1996) 312-318
37. Ladeby R., Wirenfeldt M., Garcia-Ovejero D., Fenger C., Dissing-Olesen L., Dalmau I., and Finsen B. Microglial cell population dynamics in the injured adult central nervous system. Brain Res. Brain Res. Rev. 48 2 (2005) 196-206
38. Lal M.A., Körner A., Matsuo Y., Zelenin S., Cheng S.X.J., Jaremko G., DiBona G.F., Eklöf A.-C., and Aperia A. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes 49 (2000) 1381-1389
39. Lawson L.J., Perry V.H., Dri P., and Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39 (1990) 151-170
40. Lawson L.J., Perry V.H., and Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 48 2 (1992) 405-415
41. Liu B., Jiang J.W., Wilson B.C., Du L., Yang S.N., Wang J.Y., Wu G.C., Cao X.D., and Hong J.S. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J. Pharmacol. Exp. Ther. 295 1 (2000) 125-132
42. Lu X., Bing G., and Hagg T. Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience 97 2 (2000) 285-291
43. Lumme A., Vanhatalo S., and Soinila S. Axonal transport of nitric oxide synthase in autonomic nerves. J. Autonom. Nerv. Syst. 56 3 (1996) 207-214
44. Lundström K., Tilgmann C., Peranen J., Kalkkinen N., and Ulmanen I. Expression of enzymatically active rat liver and human placental catechol-O-methyltransferase activity in Escherichia coli; purification and partial characterization of the enzyme. Acta Biochim. Biophys. 1129 2 (1992) 149-154
45. Lyras L., Zeng B.Y., McKenzie G., Pearce R.K., Halliwell B., and Jenner P. Chronic high dose l-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J. Neural Transm. 109 1 (2002) 53-67
46. Mandai M., Iwasaki M., and Honda Y. Simple and accurate assay for tyrosine hydroxylase from bovine retina by high-performance liquid chromatography with fluorescence detection. Ophthalmic Res. 24 (1992) 228-233
47. Männistö P.T., Tuomainen P., and Tuominen R.K. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br. J. Pharmacol. 105 (1992) 569-574
48. Männistö P.T., and Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51 (1999) 593-628
49. Marcocci L., Maguire J.J., and Packer L. Nitecapone: a nitric oxide radical scavenger. Biochem. Mol. Biol. Int. 34 (1994) 531-541
50. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinsons's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
51. Miyazaki I., Asanuma M., Diaz-Corrales F.J., Fukuda M., Kitaichi K., Miyoshi K., and Ogawa N. Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules. FASEB J. 20 3 (2006) 571-573
52. Narita M., Goji J., Nakamura H., and Sano K. Molecular cloning, expression, and localization of a brain-specific phosphodieserase I/nucleotide pyrophosphatase (PD-Iα) from rat brain. J. Biol. Chem. 269 45 (1994) 28235-28242
53. Ogawa N., Asanuma M., Miyazaki I., Diaz-Corrales F.J., and Miyoshi K. l-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease. J. Neurol. 252 4 (2005) 423-431
54. Ogburn K.D., Bottiglieri T., Wang Z., and Figueiredo-Pereira M.E. Prostaglandin J2 reduces catechol-O-methyltransferase activity and enchances dopamine toxicity in neuronal cells. Neurobiol. Dis. 22 2 (2006) 294-301
55. Orama M., Tilus P., Taskinen J., and Lotta T. Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution. J. Pharmacol. Sci. 86 (1997) 827-831
56. Paetau A., Elovaara I., Paasivuo R., Virtanen I., Palo J., and Haltia M. Glial elements are a major brain fraction in infantile neuronal ceroid-lipofuscinosis. Acta Neuropathol. 65 (1985) 190-194
57. Paxinos G., and Watson C. The Rats Brain in Stereotaxic Coordinates. 2nd ed. (1986), Academic Press, New York
58. Peng G.S., Li G., Tzeng N.S., Chen P.S., Chuang D.M., Hsu Y.D., Yang S., and Hong J.S. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res. Mol. Brain Res. 134 1 (2005) 162-169
59. Reenilä I., Tuomainen P., and Männistö P.T. Improved assay of catechol-O-methyltransferase (COMT) activity by high-performance liquid chromatography with coulometric detection. J. Chromatogr. B 663 (1995) 137-142
60. Reenilä I., Tuomainen P., Soinila S., and Männistö P.T. Increase of catechol-O-methyltransferase activity in rat brain microglia after intrastriatal of fluorocitrate, a glial toxin. Neurosci. Lett. 230 (1997) 155-158
61. Rivett A., Francis A., and Roth J.A. Distinct cellular localization of membrane-bound and soluble forms of catechol-O-methyltransferase in brain. J. Neurochem. 40 (1983) 215-219
62. Robinson A.P., White T.M., and Mason D.W. Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3. Immunology 57 (1986) 239-247
63. Roth J.A. Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of catecholamine neurotransmitters. Rev. Physiol. Biochem. Pharmacol. 120 (1992) 1-29
64. Roy A., Fung Y.K., Liu X., and Pahan K. Up-regulation of microglial CD11b by nitric oxide. J. Biol. Chem. 281 21 (2006) 14971-14980
65. Sasaki M., Kaneuchi M., Sakuragi N., and Dahiya R. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res. 63 (2003) 3101-3106
66. Shirakawa T., Abe M., Oshima S., Mitome M., and Oguchi H. Neuronal expression of catechol O-methyltransferase mRNA in neonatal rat suprachiasmatic nucleus. Neuroreport 15 8 (2004) 1239-1243
67. Stokes A.H., Hastings T.G., and Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55 6 (1999) 659-665
68. Storrie B., and Madden E.A. Isolation of subcellular organelles. Methods Enzymol. 182 (1990) 203-225
69. Suzuki Y.J., Tsuchiya M., Safadi A., Kagan V.E., and Packer L. Antioxidant properties of nitecapone (OR-462). Free Radic. Biol. Med. 13 (1992) 517-525
70. Ulmanen I., Peränen J., Tenhunen J., Tilgmann C., Karhunen T., Panula P., Bernasconi L., Aubry J.P., and Lundström K. Expression and intracellular localization of catechol O-methyltransferase in transfected mammalian cells. Eur. J. Biochem. 243 (1997) 452-459
71. Tomas-Camardiel M., Rite I., Herrera A.J., de Pablos R.M., Cano J., Machado A., and Venero J.L. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol. Dis. 16 1 (2004) 190-201
72. Väänänen A.J., Moed M., Tuominen R.K., Helkamaa T., Wiksten M., Liesi P., Chiueh C., and Rauhala P. Angeli's salt induces neurotoxicity in dopaminergic neurons in vivo and in vitro. Free Radic. Res. 37 4 (2003) 381-389
73. Werner P., Di Rocco A., Prikhojan A., Rempel N., Bottiglieri T., Bressman S., and Yahr M.D. COMT-dependent protection of dopaminergic neurons by methionine, dimethionine and S-adenosylmethionine (SAM) against l-dopa toxicity in vitro. Brain Res. 893 1-2 (2001) 278-281
74. Zhao W.Q., Latinwo L., Liu X.X., Lee E.S., Lamango N., and Charlton C.G. l-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. Exp. Neurol. 171 1 (2001) 127-138